Overview

Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects

Status:
Completed

Trial end date:
2016-12-09

Target enrollment:

Participant gender:

Summary

This study is designed to observe the effect of renal function on the pharmacokinetic, safety, and tolerability profiles of Ulipristal acetate following administration of a single oral dose of a 10 mg Ulipristal acetate tablet.

Phase:

Phase 1

Details

Lead Sponsor:

Allergan
Forest Laboratories

Treatments:

Ulipristal acetate